Import from '@/components/mdx'

Can I Take Vitamin B6 with Evenity (Romosozumab)?

The short answer: no known interaction, but dose matters

Vitamin B6 and romosozumab do not interact in any pharmacokinetically meaningful way. Romosozumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes, and it does not affect the pyridoxal-5-phosphate pathways through which B6 acts. The FDA prescribing information for Evenity lists no drug-drug interactions with vitamins or supplements.

"no interaction" is not the same as "take as much as you want." The risk with B6 has nothing to do with Evenity and everything to do with dose. Peripheral sensory neuropathy is well-documented with long-term B6 supplementation above approximately 200 mg/day, and some case reports have noted toxicity at doses as low as 100 mg/day taken over years. If your nails, feet, or hands are already showing signs of peripheral nerve issues from osteoporosis-related diabetes or another comorbidity, adding unnecessary high-dose B6 muddies the clinical picture.

What romosozumab actually does in your body

The sclerostin-blocking mechanism

Romosozumab binds to and inhibits sclerostin, a protein produced primarily by osteocytes that normally brakes bone formation. Blocking sclerostin produces a dual effect: bone formation goes up and bone resorption goes down, at least during the first few months of treatment. In the FRAME trial, 7,180 postmenopausal women with osteoporosis received 210 mg romosozumab subcutaneously once monthly for 12 months; the drug reduced new vertebral fractures by 73% compared with placebo at 12 months.

Why it is a monoclonal antibody, not a small molecule

Because romosozumab is a large-molecule biologic, it is not absorbed orally, not excreted through renal tubular transport alongside most supplements, and not metabolized by the liver's drug-processing enzymes. Its half-life is approximately 6.4 days after a single 210 mg subcutaneous dose. This pharmacokinetic profile means that co-administration timing windows (the kind you worry about with, say, levothyroxine and calcium) simply do not apply here.

Who receives romosozumab

Evenity is approved for postmenopausal women with osteoporosis at high risk for fracture, defined in practice as a T-score of <-2.5 plus a prior fragility fracture, or a T-score of <-3.0. The ACOG and Bone Health and Osteoporosis Foundation joint guidance notes that most women who reach this threshold are in their mid-60s or older, meaning they are well past menopause.

What vitamin B6 does, and why women take it

Physiology and forms

Pyridoxine (the supplemental form) is converted in the body to pyridoxal-5-phosphate (PLP), the active coenzyme. PLP participates in over 100 enzymatic reactions: amino acid metabolism, neurotransmitter synthesis, hemoglobin production, and homocysteine conversion. The National Institutes of Health Office of Dietary Supplements sets the Recommended Dietary Allowance at 1.3 mg/day for women aged 19 to 50, rising to 1.5 mg/day after age 50.

Why women specifically seek out B6

Women take B6 across multiple life stages for distinct reasons:

• Pregnancy nausea. B6 (pyridoxine) at 10 to 25 mg three times daily is a first-line recommendation for nausea and vomiting of pregnancy from ACOG Practice Bulletin 189. This is one of the most evidence-backed uses of B6 in women.
• PMS and PMDD. Several randomized trials suggest B6 at 50 to 100 mg/day modestly reduces premenstrual mood and physical symptoms, though effect sizes are small.
• Oral contraceptive use. Some older data suggested hormonal contraceptives deplete B6, though modern low-dose pills have much smaller effects on B6 status. Women on long-term OCs who eat a varied diet are unlikely to be clinically deficient.
• Homocysteine management. Elevated homocysteine is an independent risk factor for cardiovascular disease. B6, folate, and B12 together lower homocysteine. One meta-analysis in JAMA found B-vitamin supplementation lowered homocysteine but did not reduce cardiovascular events.
• General B-complex supplementation. Many women over 60 take a B-complex alongside calcium and vitamin D for general wellness.

The women most likely to be on romosozumab (postmenopausal, over 60) often take B6 as part of a B-complex or cardiovascular supplement. That makes this question clinically real, not just theoretical.

The Tolerable Upper Intake Level and neuropathy risk

The NIH Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for B6 at 100 mg/day for adults. Above that level, peripheral sensory neuropathy risk rises with dose and duration. Symptoms include numbness, tingling, and unsteady gait. A 1987 case series published in the New England Journal of Medicine described seven patients with sensory neuropathy who had taken 2,000 mg/day or more; later reports showed toxicity in some individuals at 200 to 500 mg/day over months. For a woman already at fracture risk, a balance-disrupting neuropathy is not a trivial adverse effect.

The interaction question, in detail

Pharmacokinetic interaction: does not exist

A pharmacokinetic (PK) interaction would mean B6 changes the absorption, distribution, metabolism, or excretion of romosozumab, or vice versa. This is biologically implausible. Monoclonal antibodies like romosozumab are catabolized into peptides and amino acids through normal protein degradation pathways. Pyridoxal-5-phosphate is a coenzyme involved in amino acid transamination, but that process occurs at a subcellular enzymatic level entirely separate from immunoglobulin catabolism. There is no shared transporter, no shared enzymatic pathway, and no evidence in the FRAME pharmacokinetic sub-study that any micronutrient altered romosozumab exposure.

Pharmacodynamic interaction: theoretical but not documented

A pharmacodynamic (PD) interaction would mean both agents affect the same physiological outcome, amplifying or opposing each other. Some investigators have hypothesized that B6 deficiency worsens bone quality indirectly through elevated homocysteine (which interferes with collagen cross-linking), and that correcting B6 status might support bone matrix. One cohort study in older adults found low plasma PLP associated with lower bone mineral density, though causality was not established. If B6 repletion does support collagen matrix integrity, it would theoretically add to, not subtract from, romosozumab's bone-building effect. No clinical trial has tested this combination directly. The data are extrapolated from observational studies, not from head-to-head or additive-effect trials.

The WomanRx Interaction Framework for Romosozumab + Supplements

Because romosozumab is a monoclonal antibody with no hepatic enzyme metabolism, the practical checklist for any supplement is simpler than it looks:

1. Does the supplement affect calcium or vitamin D absorption? (Those two directly support romosozumab's bone-building window.)
2. Does the supplement carry independent toxicity that could be mistaken for a drug side effect?
3. Does the supplement affect cardiovascular risk? (Evenity carries a boxed warning for major adverse cardiovascular events.)

Vitamin B6 at dietary or low supplemental doses scores benign on all three. High-dose B6 (above 100 mg/day) introduces the neuropathy risk described above, which is question two.

What about the cardiovascular boxed warning?

Evenity's prescribing label carries a boxed warning for serious cardiovascular events, including myocardial infarction and stroke. In the ARCH trial, which compared romosozumab followed by alendronate versus alendronate alone in 4,093 postmenopausal women, the romosozumab arm had a higher rate of serious cardiovascular events (2.5% vs 1.9%) at 24 months. B6 supplementation does not increase cardiovascular risk and may marginally lower homocysteine. There is no cardiovascular interaction concern between B6 and romosozumab.

Calcium, vitamin D, and the supplements that actually matter alongside Evenity

Romosozumab drives rapid bone formation during its 12-month treatment window. That process requires adequate substrate: calcium and vitamin D. The FRAME trial protocol required all participants to take at least 500 mg calcium and 600 IU vitamin D daily. The Bone Health and Osteoporosis Foundation recommends 1,200 mg total daily calcium (diet plus supplement) and at least 800 to 1,000 IU vitamin D3 for women over 50.

Supplements that could theoretically interfere with calcium absorption include high-dose zinc (above 50 mg/day competing at intestinal transporters) and very high-dose magnesium. B6 does not affect calcium absorption at any realistic dose. If you are taking a B-complex that includes B6, the formulation almost never contains enough B6 to cause any physiological issue.

Pregnancy, lactation, and contraception: mandatory information

Romosozumab is contraindicated in pregnancy. This is not a relative contraindication. The FDA label states explicitly that Evenity may cause fetal harm. Animal studies showed fetal skeletal abnormalities and increased neonatal mortality with romosozumab exposure during gestation. There are no adequate human data in pregnant women, and the FDA prescribing information states women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose, given the drug's half-life.

Romosozumab is approved only for postmenopausal women. In clinical practice, any premenopausal woman prescribed romosozumab off-label (an uncommon scenario in severe glucocorticoid-induced osteoporosis, for example) must be counseled explicitly about the teratogenic risk and must use highly effective contraception throughout the 12-month course and for 3 months after.

Lactation data are absent. It is not known whether romosozumab transfers into human milk. Given its molecular weight as a monoclonal antibody (approximately 136 kDa), transfer into milk is expected to be minimal, but oral bioavailability from milk would also be low because the infant's gut would degrade the antibody. The FDA label recommends weighing the benefits to the mother against the potential risks to the infant. In practice, romosozumab is not used in breastfeeding women because the approved indication is postmenopausal.

Vitamin B6 in pregnancy is safe at therapeutic doses. The ACOG recommendation for pregnancy nausea is 10 to 25 mg pyridoxine three times daily, with a long safety record. High-dose B6 (above 100 mg/day) during pregnancy is not recommended because safety data at those doses are limited. B6 transfers freely into breast milk; nursing women who take very high doses could expose their infants to supraphysiologic levels. Standard B-complex doses present no concern.

Who is right for Evenity, and who is not

Right for romosozumab

• Postmenopausal women with a T-score of <-2.5 and a prior fragility fracture, or a T-score of <-3.0, at high fracture risk.
• Women who have failed or cannot tolerate bisphosphonates or denosumab.
• Women without a recent myocardial infarction or stroke (within the past year; this is an absolute contraindication per the label).
• Women who can complete 12 consecutive monthly injections and then transition immediately to antiresorptive therapy to preserve the gains. The ACOG osteoporosis practice bulletin notes that anabolic agents should be followed by antiresorptive therapy to prevent rapid bone loss.

Not right for romosozumab

• Women who are pregnant, planning pregnancy within the next 15 months (12-month course plus 3-month washout), or breastfeeding.
• Women who had a myocardial infarction or stroke in the past 12 months.
• Women with hypocalcemia (must be corrected before starting).
• Women who cannot access monthly subcutaneous injections in a clinical setting.

Monitoring during the romosozumab course

What your clinician should check

Your prescriber should confirm normal serum calcium before each injection cycle. Hypocalcemia is a documented risk, especially in women with vitamin D deficiency. A pooled analysis of FRAME and ARCH found hypocalcemia occurred in about 3% of participants, most of whom had baseline low vitamin D.

Other monitoring:

• Serum 25-hydroxyvitamin D at baseline; target 40 to 60 ng/mL during treatment.
• Renal function (eGFR) to guide calcium supplementation decisions; women with eGFR <30 mL/min/1.73m2 were excluded from FRAME.
• Injection site reactions: erythema, pain, bruising are common (reported in about 5% of participants in FRAME).
• Osteonecrosis of the jaw and atypical femoral fractures are rare but reported class effects; risk is lower with anabolic agents than antiresorptives, and dental evaluation before treatment start is standard practice.

Where B6 fits in monitoring

If you take B6 above 100 mg/day, your clinician should know. If you develop tingling or numbness in your feet or hands during your Evenity course, do not automatically attribute it to romosozumab. High-dose B6 neuropathy is the more parsimonious explanation in a woman taking 200 mg/day or more of pyridoxine. A basic neurological exam and a medication reconciliation review (including all supplements) should precede any decision to stop Evenity.

Practical guidance: what to tell your prescriber

Bring every bottle. Not just your prescriptions. Your calcium carbonate, your B-complex, your collagen powder, your magnesium glycinate. The interaction risk from B6 alone is low, but the full picture of your supplement stack matters for safety and for monitoring.

Specifically for B6:

• If you take a standard B-complex with 2 to 25 mg B6, there is no concern. Continue as usual.
• If you take standalone B6 at 50 to 100 mg/day for PMS, premenstrual mood, or homocysteine management, flag it to your prescriber. The dose is below the UL, but documentation in your chart matters.
• If you take 200 mg/day or more for any reason, that is above the NIH Tolerable Upper Intake Level. Discuss reducing the dose or switching to a lower-dose preparation, independent of your Evenity course.

The evidence gap here is real: no clinical trial has formally studied any supplement combination with romosozumab in women, and the FRAME and ARCH trials did not systematically capture supplement use beyond calcium and vitamin D. Women have been historically under-represented in pharmacological interaction studies, and supplement-drug interaction data in postmenopausal women specifically are sparse. What we know about B6 and romosozumab comes from mechanism extrapolation, not direct study.

Life-stage summary

| Life stage | Romosozumab status | B6 considerations | |---|---|---| | Reproductive years (pre-menopause) | Not indicated; teratogenic risk requires contraception | B6 often used for PMS or OC-related depletion; standard doses safe | | Trying to conceive | Contraindicated; 3-month washout required post-last dose | B6 10-25 mg TID commonly used for nausea; safe | | Pregnancy | Absolutely contraindicated | B6 10-25 mg TID first-line for nausea (ACOG); high doses not recommended | | Postpartum / lactation | Not indicated | Standard B-complex doses safe in breastfeeding | | Perimenopause | Not yet indicated for most; DXA may detect early bone loss | B6 used by some for perimenopausal mood changes; limit to <100 mg/day | | Post-menopause | Primary approved population | B-complex use common; keep B6 below 100 mg/day |

What the evidence gap means for you

No randomized trial has tested B6 plus romosozumab. The absence of a documented interaction is reassuring, but it is not the same as a study that ruled it out. Two things are established with confidence: romosozumab's PK profile makes a direct supplement interaction biologically implausible, and high-dose B6 carries its own independent neuropathy risk at doses above 100 to 200 mg/day.

The practical clinical instruction is this: keep your B6 intake at or below 100 mg/day while on Evenity, make sure your calcium is at 1,200 mg total daily and your vitamin D is repleted, and report any new numbness or tingling to your prescriber before assuming a cause.